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E-mail address: christer.larsson@med.lu.se (C. LarsProtein kinase C (PKC) d is a regulator of apoptosis with both pro- and anti-apoptotic effects. The
mechanistic basis for the discrepant effects is not completely understood. Here we show that Smac
interacts with PKCd. The interaction depends on the N-terminus of Smac and is disrupted upon
treatment with paclitaxel. This is associated with release of Smac into the cytosol. Activation of PKCd
rescues the interaction during paclitaxel exposure and suppresses the paclitaxel-mediated cell
death. However, under these conditions the complex is mainly found in the cytosol suggesting that
cytosolic Smac can be bound by PKCd when PKC is activated. The data unravel a previously unrec-
ognized interaction and suggest that PKCd by associating with Smac may prevent its apoptotic
effects.
Structured summary of protein interactions:
PKC delta physically interacts with SMAC by anti bait coimmunoprecipitation (View Interaction: 1, 2, 3, 4)
XIAP physically interacts with SMAC by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is a programmed cell death process critically involved
in the pathogenesis of many diseases. There are two major apopto-
tic pathways, the extrinsic receptor-activated pathway and the
intrinsic mitochondrial pathway, with the latter involving the re-
lease of cytochrome c to the cytosol. Both pathways lead to activa-
tion of executioner caspases which is a critical step for apoptosis
induction.
One mitochondrial protein, beside cytochrome c, that is re-
leased into the cytosol during apoptosis is Smac [1,2]. Once in
the cytosol, Smac binds and inhibits its targets, members of the
IAP family [3,4]. Several IAPs directly counteract apoptotic path-
ways. XIAP binds and inhibits caspases [5] and cIAPs can redirect
death-receptor signaling from apoptosis induction to other effectschemical Societies. Published by E
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205 02 Malmö, Sweden.
son).[6,7]. An increase in cytosolic Smac levels should lead to a facilita-
tion of apoptosis, which has been exempliﬁed by Smac mimetics
facilitating cell death induction [8].
The apoptotic cascades are also tightly regulated by protein ki-
nases and other signal transduction mediators. The PKC isoforms
and in particular the novel PKCd are known to regulate apoptotic
pathways [9,10]. PKCd can be pro- or anti-apoptotic depending
on cell type or stimulus [11] although the pro-apoptotic function
is more common. For breast cancer cells, we have shown that PKCd
is a survival factor and that depletion of PKCd leads to apoptosis
[12]. In this study we demonstrate that PKCd associates with Smac
in breast cancer cell lines and that the interaction is disrupted dur-
ing paclitaxel-induced cell death, highlighting novel putative
mechanisms of apoptosis regulation.2. Materials and methods
2.1. Plasmids
Vectors encoding truncated Smac variants fused to the HSV tag
[13] were kindly provided by Mikihiko Naito University of Tokyo,
Japan.lsevier B.V. All rights reserved.
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Cell lines were obtained from American Type Culture Collection
and grown under standard conditions. When indicated, cells were
treated with GF109203X (Calbiochem), paclitaxel or TPA (both Sig-
ma), cells were transfected with Lipofectamine 2000 [12].A
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For PKC immunoprecipitations, cellswerewashed in ice-cold PBS
twice before addition of 500 ll of RIPA buffer (10 mM Tris–HCl, pH
7.2, 160 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
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sates were cleared by centrifugation at 14000g for 10 min.
For Smac immunoprecipitation, cells were washed in ice-cold
PBS three times before addition of 500 ll lysis buffer (20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM B-glycero-
phosphate, 1 mM EDTA, 1 mM EGTA) containing 40 ll/ml complete
protease inhibitors (Roche Applied Science) and 1 mM phenyl-
methylsulfonyl ﬂuoride. Lysates were sonicated 2  10 s and
cleared by centrifugation at 14000g for 10 min.
Immunoprecipitations were performed using antibodies to-
gether with protein G sepharose (GE Healthcare Bio-Science).
2.4. Subcellular fractionation
MCF-7 cells were washed twice in ice-cold PBS, re-suspended in
buffer [250 mM sucrose, 20 mM HEPES/KOH (pH 7.4), 10 mM KCl,A B
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trifuged for 10 min at 800g and supernatants were further used
to obtain cytosolic mitochondria-free fraction by centrifugation
at 22000g for 15 min. The resulting pellet was extracted and used
as the membrane fraction containing mitochondria.
2.5. Western blot
Membranes were blocked with PBS containing 5% non-fat milk,
and probed with antibodies towards actin (MP Biomedicals), cyto-
chrome c (BD Pharmingen), tubulin (Abcam) GFP (Zymed Laborato-
ries Inc.), PKCa, PKCd, PKCe, (Santa Cruz Biotechnology, Inc.), Smac
(Abcam), or PARP (Biomol) followed by luminescent detection
using a horseradish peroxidase-labeled secondary antibody.ne
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Cells were stained with Annexin V-APC (BD Pharmingen) and
analyzed with a FACSCalibur (Becton Dickinson). 10,000 events
were acquired on the FL-4 channel for the Annexin V-APC signal.
Sample acquisition and analyses were performed with CellQuest
software (Becton Dickinson).IP: PKCδ
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3.1. PKCd and Smac interact in breast cancer cell lines
In a screen for PKCd-interacting proteins by mass spectrometry
analysis of trypsin-digested proteins present in PKCd precipitates,
one protein of putative relevance was identiﬁed. This protein was
Smac. To conﬁrm the interaction, lysates from cultured cells were
immunoprecipitated with antibodies against PKCd or Smac
(Fig. 1A–D and F). Smac could be detected in PKCd precipitates in
the cell lines investigated but the interaction was not as evident
in some cell lines including PC3, SK-N-BE(2)C, DU-145, nd HeLa
cells (Fig. 1A, C and F). Conversely, PKCd associated with immuno-
precipitated Smac in MDA-MB-231 and MCF-7 cells, although only
a weak Smac band was detected for the latter cell type (Fig. 1B and
D). Lysates fromMDA-MB-231 cells were also immunoprecipitated
with antibodies towards PKCa, PKCd, or PKCe. Smac was only
found in PKCd precipitates (Fig. 1E).
To analyze the region of importance for the interaction in the
Smac molecule, a series of HSV-tag fusions of Smac deletions wereTPA
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the mitochondria. Most PKCdmolecules are conceivably in the cytosol. Paclitaxel induces
cell death induction. TPA leads to the interaction of PKCd with cytosolic Smac and the
different combinations of vectors encoding PKCdRD-EGFP, Smac–FLAG, and HA-XIAP.
precipitates were analyzed with Western blot. Arrows beside the GFP blot indicate free E
from the HA detection. (D) Intensities were quantiﬁed and ratio of Smac–FLAG in precip
HA-XIAP. Data are mean ± SEM (n = 3). ⁄⁄⁄ indicates statistically signiﬁcant differences (expressed in MCF-7 cells (Fig. 1G). Endogenous PKCd co-precipi-
tated full-length Smac and Smac truncated after the mitochondrial
localization signal. However PKCd did not associate with Smac,
truncated at amino acid 60 and thus lacking amino acids 55–59.
This is the part of Smac that is responsible for its interaction with
IAPs [3,4,14]. For full-length Smac a variant approximately 6 kDa
larger than the major Smac species, conceivably representing
pro-Smac, was also co-precipitated with PKCd.
3.2. The PKCd–Smac interaction is disrupted upon paclitaxel-mediated
induction of cell death
Since Smac is frequently released from mitochondria upon
induction of apoptosis [1] the interaction was studied during cell
death induction. Paclitaxel induced a gradual dissociation of the
complex in both MCF-7 (Fig. 2A and D) and MDA-MB-468 cells
(Fig. 2B and E) but not in MDA-MB-231 cells (Fig. 2C) which are rel-
atively insensitive to paclitaxel. There was also a decrease in total
Smac levels, which was most obvious after 48 h. However, total
Smac levels were generally the same after 12 and 24 h of paclitaxelIn
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gesting that the dissociation precedes a plausible degradation of
Smac.
We next investigated if the release of Smac from mitochondria
occurs in conjunction with the disruption of the PKCd–Smac com-
plex (Fig. 2F). There was a slight increase in cytosolic Smac levels
after 12 h of paclitaxel treatment, which rose further after 24 h.
There was also an increase in cytosolic cytochrome c upon pro-
longed paclitaxel exposure. As a further indicator of cell death,
PARP cleavage was detected in paclitaxel-treated MDA-MB-468
cell after 24 h (G). In MCF-7 cells, a corresponding decrease in
full-length PARP was seen but no cleavage products were observed.
There seems to be a temporal relationship between the PKCd–Smac
disruption, release of Smac and cytochrome c, and PARP cleavage
since all the events started between 12 and 24 h of paclitaxel
treatment.
3.3. Activation of PKC prevents paclitaxel-induced cell death and
dissociation of PKCd–Smac
We next studied whether the PKC activator TPA or the PKC
inhibitor GF109203X inﬂuences the interaction (Fig. 3A). Inclusion
of TPA during paclitaxel exposure of MCF-7 cells resulted in a
maintained interaction of Smac with PKCd (Fig. 3A, lane 5).
GF109203X abolished the TPA-mediated maintenance of the inter-
action (Fig. 3A, lane 8).
We next investigated if the state of the PKCd–Smac complex
correlates with induction of cell death. Exposure to paclitaxel re-
duced the number of viable MCF-7 cells (Fig. 3B) and increased
the amount of Annexin V-positive cells (Fig. 3C). Exposure to TPA
reversed the effects of paclitaxel. Furthermore, GF109203X inhib-
ited the TPA effects but not the effects of paclitaxel alone, which
is in line with its effect on paclitaxel-mediated disruption of the
PKCd–Smac complex shown in Fig. 3A (lanes 6 and 8). The data
demonstrate a correlation between maintained PKCd–Smac inter-
action and cell survival.
3.4. Following release of Smac the interaction with PKCd takes place in
the cytosol
To further analyze the interaction between PKCd and Smac,
PKCd was immunoprecipitated from a cytosolic fraction and a
membrane fraction containing mitochondria. In the presence of
TPA and paclitaxel the PKCd–Smac complex is largely found in
the cytosolic fraction. Thus, the TPA-mediated maintenance of
the PKCd–Smac interaction in the presence of paclitaxel (Fig. 4A)
mainly takes place in the cytosol.
TPA alters the conformation and activates PKCd. Since the TPA
effect was suppressed by PKC inhibition with GF109203X (Fig. 3)
it is conceivable that the interaction in the cytosol is dependent
on PKC activity. However, under basal conditions, when the inter-
action does not take place in the cytosol but presumably in the
mitochondria, neither TPA nor GF109203X inﬂuenced the interac-
tion. It indicates that other factors, perhaps present only in mito-
chondria, facilitate the interaction under normal growth
conditions. A hypothetical model for the PKCd–Smac interaction
is shown in Fig. 4B.
3.5. High levels of PKCd suppress the interaction of XIAP with Smac
Smac can bind and inhibit the function of IAPs facilitating the
induction of apoptosis. One putative effect of the interaction with
PKCd could be a sequestration of Smac which would prevent it
from binding IAPs. Such a model is supported by the ﬁnding that
the interaction with PKCd depends on the IAP-binding site in Smac
(Fig. 1G). To further test the model, COS-7 cells were transfectedwith vectors encoding Smac–FLAG, HA-XIAP and/or the regulatory
domain of PKCd fused to EGFP (PKCdRD-EGFP). When PKCdRD was
not included immunoprecipitation of XIAP using the HA tag pulled
down Smac–FLAG (Fig. 4C and D). However, when PKCdRD was co-
expressed markedly less Smac–FLAG co-precipitated with HA-
XIAP.
3.6. Concluding remarks
We provide a speculative model for the role of PKCd in regulat-
ing Smac in Fig. 4B. Under basal conditions it is suggested that
PKCd and Smac mainly interacts in the mitochondria. Upon paclit-
axel treatment the complex dissociates and Smac is released into
the cytosol where it is of importance for cell death induction. Un-
der these conditions, TPA promotes the interaction between PKCd
and Smac, which thereby could prevent Smac from exerting its
function. Our data indicate that this could have important regula-
tory roles in paclitaxel-induced death. It remains to be investigated
the importance of the interaction for other cell death stimuli and
other cell types. Our data indicate that the interaction per se takes
place in several different cells.
PKCd has generally been considered to have pro-apoptotic ef-
fects. It has among others been shown to play a role both upstream
in the intrinsic pathway leading to cytochrome c release [15] and
as a critical substrate for and activator of executioner caspases
[16]. Moreover, translocation of PKCd to mitochondria or the nu-
cleus has been associated with induction of apoptosis in many cell
types [17–20]. However, in breast cancer cells PKCd is rather a sur-
vival factor [12,21,22].
Smac has, similar to PKCd, cell-speciﬁc effects, as shown by
studies with Smac mimetics which have revealed that some cells
are highly sensitive to these agents whereas others are essentially
resistant as exempliﬁed for breast cancer cells [23]. Since the inter-
action of PKCd with Smac is associated with survival in our exper-
iments, it suggests a mechanism that could at least partially
explain an anti-apoptotic effect of PKCd. These facts provide for
cell-speciﬁc conditions that could determine whether PKCd has
primarily an anti- or pro-apoptotic role.
In conclusion, we demonstrate a previously uncharacterized
interaction between two proteins, PKCd and Smac, critically in-
volved in the regulation of apoptotic pathways. The interaction
could conceivably prevent Smac from exerting its functions and
may be an important mechanism regulating apoptosis.Acknowledgments
This work was supported by grants from the Swedish Research
Council, the Swedish Cancer Society, the Gunnar Nilsson, Crafoord,
Ollie and Elof Ericsson, and Kock foundations, and Malmo Univer-
sity Hospital research funds.References
[1] Du, C., Fang, M., Li, Y., Li, L. and Wang, X. (2000) Smac, a mitochondrial protein
that promotes cytochrome c-dependent caspase activation by eliminating IAP
inhibition. Cell 102, 33–42.
[2] Verhagen, A.M. et al. (2000) Identiﬁcation of DIABLO, a mammalian protein
that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102,
43–53.
[3] Liu, Z. et al. (2000) Structural basis for binding of Smac/DIABLO to the XIAP
BIR3 domain. Nature 408, 1004–1008.
[4] Wu, G., Chai, J., Suber, T.L., Wu, J.W., Du, C., Wang, X. and Shi, Y. (2000)
Structural basis of IAP recognition by Smac/DIABLO. Nature 408, 1008–1012.
[5] Deveraux, Q.L., Takahashi, R., Salvesen, G.S. and Reed, J.C. (1997) X-linked IAP
is a direct inhibitor of cell-death proteases. Nature 388, 300–304.
[6] Varfolomeev, E. et al. (2007) IAP antagonists induce autoubiquitination of c-
IAPs, NF-jB activation, and TNFa-dependent apoptosis. Cell 131, 669–681.
[7] Vince, J.E. et al. (2007) IAP antagonists target cIAP1 to induce TNFa-dependent
apoptosis. Cell 131, 682–693.
1172 K.C. Masoumi et al. / FEBS Letters 586 (2012) 1166–1172[8] Fulda, S., Wick, W., Weller, M. and Debatin, K.M. (2002) Smac agonists
sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce
regression of malignant glioma in vivo. Nat. Med. 8, 808–815.
[9] Reyland, M.E. (2007) Protein kinase Cd and apoptosis. Biochem. Soc. Trans. 35,
1001–1004.
[10] Griner, E.M. and Kazanietz, M.G. (2007) Protein kinase C and other
diacylglycerol effectors in cancer. Nat. Rev. Cancer 7, 281–294.
[11] Brodie, C. and Blumberg, P.M. (2003) Regulation of cell apoptosis by protein
kinase c d. Apoptosis 8, 19–27.
[12] Lonne, G.K., Masoumi, K.C., Lennartsson, J. and Larsson, C. (2009) Protein
kinase Cd supports survival of MDA-MB-231 breast cancer cells by
suppressing the ERK1/2 pathway. J. Biol. Chem. 284, 33456–33465.
[13] Hao, Y. et al. (2004) Apollon ubiquitinates SMAC and caspase-9, and has an
essential cytoprotection function. Nat. Cell Biol. 6, 849–860.
[14] Srinivasula, S.M., Datta, P., Fan, X.J., Fernandes-Alnemri, T., Huang, Z. and
Alnemri, E.S. (2000) Molecular determinants of the caspase-promoting
activity of Smac/DIABLO and its role in the death receptor pathway. J. Biol.
Chem. 275, 36152–36157.
[15] Sitailo, L.A., Tibudan, S.S. and Denning, M.F. (2004) Bax activation and
induction of apoptosis in human keratinocytes by the protein kinase C d
catalytic domain. J. Invest. Dermatol. 123, 434–443.
[16] Emoto, Y. et al. (1995) Proteolytic activation of protein kinase C d by an ICE-
like protease in apoptotic cells. EMBO J. 14, 6148–6156.[17] DeVries, T.A., Neville, M.C. and Reyland, M.E. (2002) Nuclear import of PKCd is
required for apoptosis: identiﬁcation of a novel nuclear import sequence.
EMBO J. 21, 6050–6060.
[18] Li, L., Lorenzo, P.S., Bogi, K., Blumberg, P.M. and Yuspa, S.H. (1999) Protein
kinase Cd targets mitochondria, alters mitochondrial membrane potential, and
induces apoptosis in normal and neoplastic keratinocytes when
overexpressed by an adenoviral vector. Mol. Cell Biol. 19, 8547–8558.
[19] Majumder, P.K., Pandey, P., Sun, X., Cheng, K., Datta, R., Saxena, S., Kharbanda,
S. and Kufe, D. (2000) Mitochondrial translocation of protein kinase C d in
phorbol ester-induced cytochrome c release and apoptosis. J. Biol. Chem. 275,
21793–21796.
[20] Sumitomo, M., Ohba, M., Asakuma, J., Asano, T., Kuroki, T., Asano, T. and
Hayakawa, M. (2002) Protein kinase Cd ampliﬁes ceramide formation via
mitochondrial signaling in prostate cancer cells. J. Clin. Invest. 109, 827–836.
[21] McCracken, M.A., Miraglia, L.J., McKay, R.A. and Strobl, J.S. (2003) Protein
kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol.
Cancer Ther. 2, 273–281.
[22] Nabha, S.M., Glaros, S., Hong, M., Lykkesfeldt, A.E., Schiff, R., Osborne, K. and
Reddy, K.B. (2005) Upregulation of PKC-5 contributes to antiestrogen
resistance in mammary tumor cells. Oncogene 24, 3166–3176.
[23] Bockbrader, K.M., Tan, M. and Sun, Y. (2005) A small molecule Smac-mimic
compound induces apoptosis and sensitizes TRAIL- and etoposide-induced
apoptosis in breast cancer cells. Oncogene 24, 7381–7388.
